Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
33%(2 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
3
38%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (62.5%)
Phase 23 (37.5%)

Trials by Status

completed675%
terminated113%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Study of AT-527 in Subjects With Normal and Impaired Renal Function

NCT05618314
terminatedphase_2

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

NCT04396106
completedphase_2

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

NCT04709835
completedphase_1

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

NCT05256732
withdrawnphase_1

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

NCT04309734
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05618314Phase 1

Study of AT-527 in Subjects With Normal and Impaired Renal Function

Completed
NCT04396106Phase 2

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

Terminated
NCT04709835Phase 2

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

Completed
NCT05256732Phase 1

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

Completed
NCT04309734Phase 1

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Withdrawn
NCT04877769Phase 1

Bronchopulmonary PK of AT-527 (R07496998)

Completed
NCT04019717Phase 2

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Completed
NCT03219957Phase 1

Study of AT-527 in Healthy and HCV-Infected Subjects

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8